Company intelligence / Profile preview

DermiPsor Ltd.

Israel

Ownership: Private
Development stage: Other

Overview

DermiPsor developed a topical cream for psoriasis that demonstrated safety and superior efficacy over placebo in a Phase II trial involving 168 patients at five US medical centers. The company advanced to Phase III clinical trials following these results.

No recent updates on trial completion or commercialization are available.

Therapeutic areas: Dermatology
Modalities: Topical cream (likely small molecule or combination therapy for dermatological use)
Industry: Biotech

Partnerships

Meytag Technology Incubator supported/incubated the company during development phase

Beyond the preview

Go deeper on DermiPsor Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermiPsor Ltd..